Why Are Novavax Shares Trading Lower Today?
Why Are Novavax Shares Trading Lower Today?
Novavax Inc. (NASDAQ:NVAX) shares are on watch Thursday. Here's a recap of recent events.
週四，Novavax Inc.（納斯達克股票代碼：NVAX）的股票值得關注。以下是近期事件的回顧。
Key Developments:
主要進展：
- Short Interest: Novavax's short interest has fallen, signaling that fewer investors are betting against the stock. It would take about 3.09 days to cover all short positions based on average trading volumes.
- FDA Approval: Novavax's updated COVID-19 vaccine has been approved and will be available at thousands of locations across the U.S., including retail pharmacies and grocers. This approval strengthens Novavax's position in the market as it continues to offer a unique protein-based vaccine alternative.
- Revenue Guidance: In August, Novavax lowered its 2024 revenue guidance to between $700 million and $800 million, significantly below earlier projections.
- 空頭利息：Novavax的空頭利率有所下降，這表明押注該股的投資者越來越少。根據平均交易量，填補所有空頭頭寸大約需要3.09天。
- 美國食品藥品管理局批准：Novavax更新後的 COVID-19 疫苗已獲得批准，將在美國數千個地點上市，包括零售藥房和雜貨店。這一批准鞏固了Novavax在市場上的地位，因爲它將繼續提供獨特的基於蛋白質的疫苗替代品。
- 收入指導：8月，Novavax將其2024年的收入預期下調至7億至8億美元之間，大大低於先前的預期。
In comparison, Moderna Inc. (NASDAQ:MRNA) also shared updates during its R&D day, projecting 2025 revenues of $2.5 billion to $3.5 billion, below the consensus of $3.74 billion. The company is cutting its R&D budget by $1.1 billion by 2027 and focusing on ten prioritized products. Despite lower-than-expected revenue forecasts, Moderna remains confident in its long-term growth and cash reserves.
相比之下，摩德納公司（納斯達克股票代碼：MRNA）也在研發日分享了最新情況，預計2025年收入爲25億美元至35億美元，低於市場預期的37.4億美元。該公司將在2027年之前將其研發預算削減11億美元，並將重點放在十種優先產品上。儘管收入預測低於預期，但Moderna對其長期增長和現金儲備仍然充滿信心。
NVAX Price Action: Novavax shares were down by 2.48% at $11.99 according to Benzinga Pro.
NVAX價格走勢：根據Benzinga Pro的數據，Novavax股價下跌2.48％，至11.99美元。
- Jim Cramer Sees Opportunity In Micron Stock As Death Cross, Earnings Approach
- 吉姆·克萊默認爲，隨着死亡的臨近，美光股票的機會即將來臨
Photo via Shutterstock.
照片來自 Shutterstock。